vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $7.6M, roughly 1.6× Marygold Companies, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -7.5%, a 258.2% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -4.5%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -1.5%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
MGLD vs SPRO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $12.6M |
| Net Profit | $-576.0K | $31.5M |
| Gross Margin | 74.0% | — |
| Operating Margin | -8.3% | — |
| Net Margin | -7.5% | 250.7% |
| Revenue YoY | -4.5% | 24080.8% |
| Net Profit YoY | 67.0% | 250.9% |
| EPS (diluted) | $-0.01 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $12.6M | ||
| Q3 25 | $7.0M | $0 | ||
| Q2 25 | $7.2M | $0 | ||
| Q1 25 | $7.0M | $12.0K | ||
| Q4 24 | $8.0M | $52.0K | ||
| Q3 24 | $7.9M | $65.0K | ||
| Q2 24 | $8.3M | $114.0K | ||
| Q1 24 | $7.9M | $140.0K |
| Q4 25 | $-576.0K | $31.5M | ||
| Q3 25 | $-356.0K | $-7.4M | ||
| Q2 25 | $-1.5M | $-1.7M | ||
| Q1 25 | $-1.0M | $-13.9M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.6M | $-17.1M | ||
| Q2 24 | $-1.9M | $-17.9M | ||
| Q1 24 | $-529.0K | $-12.7M |
| Q4 25 | 74.0% | — | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 75.0% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 72.5% | — | ||
| Q1 24 | 70.5% | — |
| Q4 25 | -8.3% | — | ||
| Q3 25 | -18.2% | — | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -21.4% | -122758.3% | ||
| Q4 24 | -22.8% | — | ||
| Q3 24 | -27.4% | -28604.6% | ||
| Q2 24 | -33.3% | -16720.2% | ||
| Q1 24 | -18.7% | -9987.1% |
| Q4 25 | -7.5% | 250.7% | ||
| Q3 25 | -5.1% | — | ||
| Q2 25 | -20.4% | — | ||
| Q1 25 | -14.4% | -115550.0% | ||
| Q4 24 | -21.8% | — | ||
| Q3 24 | -20.1% | -26380.0% | ||
| Q2 24 | -22.5% | -15668.4% | ||
| Q1 24 | -6.7% | -9049.3% |
| Q4 25 | $-0.01 | $0.56 | ||
| Q3 25 | $-0.01 | $-0.13 | ||
| Q2 25 | $-0.04 | $-0.03 | ||
| Q1 25 | $-0.02 | $-0.25 | ||
| Q4 24 | $-0.04 | — | ||
| Q3 24 | $-0.04 | $-0.32 | ||
| Q2 24 | $-0.05 | $-0.33 | ||
| Q1 24 | $-0.01 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $59.0M |
| Total Assets | $27.8M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $40.3M | ||
| Q3 25 | $12.5M | $48.6M | ||
| Q2 25 | $12.8M | $31.2M | ||
| Q1 25 | $15.6M | $48.9M | ||
| Q4 24 | $14.9M | $52.9M | ||
| Q3 24 | $17.5M | $76.3M | ||
| Q2 24 | $15.0M | $63.5M | ||
| Q1 24 | $16.1M | $82.3M |
| Q4 25 | $22.7M | $59.0M | ||
| Q3 25 | $22.9M | $26.5M | ||
| Q2 25 | $23.0M | $32.8M | ||
| Q1 25 | $24.3M | $33.8M | ||
| Q4 24 | $23.4M | $46.1M | ||
| Q3 24 | $25.5M | $65.5M | ||
| Q2 24 | $26.6M | $80.5M | ||
| Q1 24 | $28.4M | $96.2M |
| Q4 25 | $27.8M | $68.9M | ||
| Q3 25 | $28.4M | $54.2M | ||
| Q2 25 | $30.4M | $62.1M | ||
| Q1 25 | $33.5M | $77.7M | ||
| Q4 24 | $33.0M | $110.5M | ||
| Q3 24 | $35.9M | $135.2M | ||
| Q2 24 | $32.9M | $149.9M | ||
| Q1 24 | $33.7M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-8.4M | ||
| Q3 25 | $-533.0K | $17.4M | ||
| Q2 25 | $-3.3M | $-17.7M | ||
| Q1 25 | $-1.2M | $-4.0M | ||
| Q4 24 | $-770.0K | $-23.4M | ||
| Q3 24 | $-893.0K | $12.8M | ||
| Q2 24 | $-1.9M | $-18.7M | ||
| Q1 24 | $-658.0K | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-562.0K | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-776.0K | — | ||
| Q3 24 | $-940.0K | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -8.1% | — | ||
| Q2 25 | -46.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -9.7% | — | ||
| Q3 24 | -11.9% | — | ||
| Q2 24 | -23.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
SPRO
Segment breakdown not available.
